Links between metabolism and cancer have been documented broadly, connecting obesity to increased cancer rates and alterations of cancer genes to cell metabolism. It is hypothesized that a deeper understanding of cancer cell metabolism would provide avenues toward new therapeutics that could be strategically deployed with currently available therapies to prevent or treat cancers. Proof-of-concept for targeting different metabolic enzymes such as fatty acid synthase, lactate dehydrogenase, and glutaminase has been provided with different tumor xenograft models. However, normal proliferating cells tend to use similar pathways to build cell mass and produce ATP. Normal tissues display metabolic circadian rhythms regulated by the master clock transcription factors that are centrally synchronized via diffusible factors from the brain's suprachiasmatic nucleus that is responsive to light. Preliminary data have documented that the MYC oncogene can disrupt the cellular circadian rhythm by directly regulating components of the Clock machinery, thereby uncoupling sustained tumor metabolism from circadian regulation, while normal cells continue to display peaks and nadirs of metabolic activity. To reach the goal of understanding oncogenic circadian disruption for optimal metabolic cancer therapy timed when normal metabolic rates are lowest while cancer metabolic rates remain elevated, three aims are set in this proposal.
Aim 1. To test the hypothesis that Myc induction of Rev-erb? alters metabolism and contributes to tumorigenesis.
Aim 2. To test the hypothesis that Myc disruption of circadian gene expression alters cellular circadian metabolism as well as human cancer cell sensitivity to metabolic inhibitors in vitro.
Aim 3. To test the hypothesis that metabolic therapy administered at specific times of the day will result in better survival using a mouse model of MYC-induced hepatocellular carcinoma.

Public Health Relevance

Novel approaches are required to curb the projected world-wide epidemic of cancers over the next several decades. The promise of exploiting changes in cancer metabolism for therapy is heightened by our innovation to exploit differences between the daily cyclic changes of normal cell metabolism and the high level of metabolism in cancer driven by the MYC cancer gene. This proposal innovates by considering the time component which could provide a therapeutic window such that treatments at specific times of the day would spare normal tissues while severely damaging cancer cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA051497-23A1
Application #
8653122
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Spalholz, Barbara A
Project Start
1990-01-01
Project End
2019-05-31
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
23
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Stine, Zachary E; Walton, Zandra E; Altman, Brian J et al. (2015) MYC, Metabolism, and Cancer. Cancer Discov 5:1024-39
Hsieh, Annie L; Walton, Zandra E; Altman, Brian J et al. (2015) MYC and metabolism on the path to cancer. Semin Cell Dev Biol 43:11-21
Altman, Brian J; Hsieh, Annie L; Sengupta, Arjun et al. (2015) MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells. Cell Metab 22:1009-19
Korangath, Preethi; Teo, Wei Wen; Sadik, Helen et al. (2015) Targeting Glutamine Metabolism in Breast Cancer with Aminooxyacetate. Clin Cancer Res 21:3263-73
Xiang, Yan; Stine, Zachary E; Xia, Jinsong et al. (2015) Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. J Clin Invest 125:2293-306
Yan, Xiaohui; Hu, Zhongyi; Feng, Yi et al. (2015) Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers. Cancer Cell 28:529-40
Rajeshkumar, N V; Dutta, Prasanta; Yabuuchi, Shinichi et al. (2015) Therapeutic Targeting of the Warburg Effect in Pancreatic Cancer Relies on an Absence of p53 Function. Cancer Res 75:3355-64
Le, Anne; Stine, Zachary E; Nguyen, Christopher et al. (2014) Tumorigenicity of hypoxic respiring cancer cells revealed by a hypoxia-cell cycle dual reporter. Proc Natl Acad Sci U S A 111:12486-91
Dang, Chi V (2013) MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harb Perspect Med 3:
Le, Anne; Rajeshkumar, N V; Maitra, Anirban et al. (2012) Conceptual framework for cutting the pancreatic cancer fuel supply. Clin Cancer Res 18:4285-90

Showing the most recent 10 out of 22 publications